Thomson Reuters Enhances MetaCore Solution with Validated Biomarker Data
Philadelphia, PA, London, UK, — Thomson Reuters today announced that it is to offer access to its validated biomarker content within MetaCore™, the company’s pathway analysis and biomarker discovery solution. The announcement marks a further step forward in providing the life sciences industry with unparalleled resources for biomarker discovery and development.
The enhanced access will provide users of MetaCore with additional gene and biomarker data including biomarker name, type and role as well as gene name within their search results. The additional data is drawn from Thomson Reuters IntegritySM, the industry’s largest source of validated biomarker data, with more than 7,000 biomarkers and 200,000 related uses. The development will provide deeper insight into potential biomarkers identified in MetaCore, including previous utility, extent of research already performed and level of confidence in that biomarker.
“Biomarkers are playing an increasingly important role in the development of new drugs and treatments,” said Jon Brett-Harris, executive vice president, Thomson Reuters. “This latest addition to MetaCore marks the first step towards a comprehensive solution for biomarker discovery, hypothesis testing and validation, enabling scientists to go from basic ‘omics’ data to biomarker insight in hours.”
Inclusion of the biomarkers data in MetaCore will strengthen its appeal among scientists and researchers working in translational medicine, or involved in the identification of biomarkers for use in internal decision making for early research and development projects.
MetaCore is an integrated solution and software suite for pathway analysis of experimental data and gene lists. The solution enables scientists to discover and hypothesize on potential new biomarkers, either through pathway exploration or through the interpretation of experimentally derived ‘omics’ data.
Thomson Reuters Integrity integrates biology, chemistry and pharmacology data on more than 340,000 compounds with demonstrated biological activity and almost 160,000 patent family records providing researchers with reliable, detailed information across multiple disciplines.
The life sciences business of Thomson Reuters works closely with the pharmaceutical, biotechnology, and academic research communities to deliver solutions that provide a better understanding of the underlying mechanism of disease and potential therapies.
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.